Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease
According to a new announcement, Brenig Therapeutics has initiated a first-in-human trial to test the efficacy and safety of its investigational best-in-class LRRK2 inhibitor BT-267 as a potential therapy to treat Parkinson disease (PD). The study, which …